If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Benchmarking Reports » Medical Affairs » Launch Optimization
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Download FREE Excerpt
Industries Profiled: Biotech; Pharmaceutical; Consulting; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Clinical Research; Laboratories Companies Profiled: Amgen; Insyght; Astellas; Incyte; Axon Pharma; Bayer; Baxter BioScience; Boehringer Ingelheim; Eisai; Insys Therapeutics; Jazz Pharmaceuticals; Janssen; Lundbeck; Medunik Canada; Merck; Merz Pharma; Onyx Pharmaceuticals; Pfizer; ProStrakan; Purdue Pharma; Sanofi; UCB Pharma; Upsher-Smith; Xenoport
Study Snapshot Best Practices, LLC engaged 28 executives from 24 leading biopharmaceutical companies within mature markets. Segmentation analysis was key to examining trends and effective practices. Research analysts also conducted deep-dive interviews with 5 selected Medical Affairs executives- 4 VPs and 1 Sr. Medical Affairs Director.
Key Findings Medical Affairs’ Role in Launch Activities: Medical Affairs is heavily involved in five launch activities within participating organizations: Scientific Publications, MSL Activities, Advisory Boards, TL identification and development. Launch Investment: On average, total launch investment increased by 16% after launch within the benchmark class.
Table of Contents Executive Summary pp. 3-11